Literature DB >> 23239884

The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205.

Mai N Tran1, Woonyoung Choi, Matthew F Wszolek, Neema Navai, I-Ling C Lee, Giovanni Nitti, Sijin Wen, Elsa R Flores, Arlene Siefker-Radtke, Bogdan Czerniak, Colin Dinney, Michelle Barton, David J McConkey.   

Abstract

Epithelial-mesenchymal transition (EMT) is a physiological process that plays important roles in tumor metastasis, "stemness," and drug resistance. EMT is typically characterized by the loss of the epithelial marker E-cadherin and increased expression of EMT-associated transcriptional repressors, including ZEB1 and ZEB2. The miR-200 family and miR-205 prevent EMT through suppression of ZEB1/2. p53 has been implicated in the regulation of miR-200c, but the mechanisms controlling miR-205 expression remain elusive. Here we report that the p53 family member and p63 isoform, ΔNp63α, promotes miR-205 transcription and controls EMT in human bladder cancer cells. ΔNp63α, E-cadherin and miR-205 were coexpressed in a panel of bladder cancer cell lines (n = 28) and a cohort of primary bladder tumors (n = 98). Stable knockdown of ΔNp63α in the "epithelial" bladder cancer cell line UM-UC6 decreased the expression of miR-205 and induced the expression of ZEB1/2, effects that were reversed by expression of exogenous miR-205. Conversely, overexpression of ΔNp63α in the "mesenchymal" bladder cancer cell line UM-UC3 induced miR-205 and suppressed ZEB1/2. ΔNp63α knockdown reduced the expression of the primary and mature forms of miR-205 and the miR-205 "host" gene (miR-205HG) and decreased binding of RNA Pol II to the miR-205HG promoter, inhibiting miR-205HG transcription. Finally, high miR-205 expression was associated with adverse clinical outcomes in bladder cancer patients. Together, our data demonstrate that ΔNp63α-mediated expression of miR-205 contributes to the regulation of EMT in bladder cancer cells and identify miR-205 as a molecular marker of the lethal subset of human bladder cancers.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239884      PMCID: PMC3561548          DOI: 10.1074/jbc.M112.408104

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development.

Authors:  A Yang; R Schweitzer; D Sun; M Kaghad; N Walker; R T Bronson; C Tabin; A Sharpe; D Caput; C Crum; F McKeon
Journal:  Nature       Date:  1999-04-22       Impact factor: 49.962

Review 2.  Epidemiology and etiology of bladder cancer.

Authors:  S L Johansson; S M Cohen
Journal:  Semin Surg Oncol       Date:  1997 Sep-Oct

3.  Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes.

Authors:  Scott Baskerville; David P Bartel
Journal:  RNA       Date:  2005-03       Impact factor: 4.942

4.  Definition of a consensus binding site for p53.

Authors:  W S el-Deiry; S E Kern; J A Pietenpol; K W Kinzler; B Vogelstein
Journal:  Nat Genet       Date:  1992-04       Impact factor: 38.330

5.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.

Authors:  A Yang; M Kaghad; Y Wang; E Gillett; M D Fleming; V Dötsch; N C Andrews; D Caput; F McKeon
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

6.  DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells.

Authors:  Andreas Eger; Kirsten Aigner; Stefan Sonderegger; Brigitta Dampier; Susanne Oehler; Martin Schreiber; Geert Berx; Amparo Cano; Hartmut Beug; Roland Foisner
Journal:  Oncogene       Date:  2005-03-31       Impact factor: 9.867

7.  Identification of mammalian microRNA host genes and transcription units.

Authors:  Antony Rodriguez; Sam Griffiths-Jones; Jennifer L Ashurst; Allan Bradley
Journal:  Genome Res       Date:  2004-09-13       Impact factor: 9.043

8.  P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.

Authors:  D F Jarrard; R Paul; A van Bokhoven; S H Nguyen; G S Bova; M J Wheelock; K R Johnson; J Schalken; M Bussemakers; W B Isaacs
Journal:  Clin Cancer Res       Date:  1997-11       Impact factor: 12.531

Review 9.  p63: Molecular complexity in development and cancer.

Authors:  Matthew D Westfall; Jennifer A Pietenpol
Journal:  Carcinogenesis       Date:  2004-03-19       Impact factor: 4.944

10.  Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms.

Authors:  F Koga; S Kawakami; J Kumagai; T Takizawa; N Ando; G Arai; Y Kageyama; K Kihara
Journal:  Br J Cancer       Date:  2003-03-10       Impact factor: 7.640

View more
  71 in total

1.  ΔNp63α Promotes Breast Cancer Cell Motility through the Selective Activation of Components of the Epithelial-to-Mesenchymal Transition Program.

Authors:  Tuyen T Dang; Matthew A Esparza; Erin A Maine; Jill M Westcott; Gray W Pearson
Journal:  Cancer Res       Date:  2015-08-19       Impact factor: 12.701

2.  p63 inhibits extravillous trophoblast migration and maintains cells in a cytotrophoblast stem cell-like state.

Authors:  Yingchun Li; Matteo Moretto-Zita; Sandra Leon-Garcia; Mana M Parast
Journal:  Am J Pathol       Date:  2014-10-07       Impact factor: 4.307

3.  ΔNp63α Silences a miRNA Program to Aberrantly Initiate a Wound-Healing Program That Promotes TGFβ-Induced Metastasis.

Authors:  Lidia Rodriguez Calleja; Camille Jacques; François Lamoureux; Marc Baud'huin; Marta Tellez Gabriel; Thibaut Quillard; Debashish Sahay; Pierre Perrot; Jerome Amiaud; Celine Charrier; Regis Brion; Fernando Lecanda; Franck Verrecchia; Dominique Heymann; Leif W Ellisen; Benjamin Ory
Journal:  Cancer Res       Date:  2016-03-17       Impact factor: 12.701

Review 4.  [Modern networks : Topics in the working group "Bladder cancer research" of the GeSRU Academics].

Authors:  S Hofbauer; C Kalogirou; F Roghmann; A-K Seitz; S Vallo; F Wezel; T Worst; R Nawroth
Journal:  Urologe A       Date:  2017-02       Impact factor: 0.639

5.  Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells.

Authors:  Kathryn E Yoh; Kausik Regunath; Asja Guzman; Seung-Min Lee; Neil T Pfister; Olutosin Akanni; Laura J Kaufman; Carol Prives; Ron Prywes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-28       Impact factor: 11.205

6.  Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Authors:  Marcin P Iwanicki; Hsing-Yu Chen; Claudia Iavarone; Ioannis K Zervantonakis; Taru Muranen; Marián Novak; Tan A Ince; Ronny Drapkin; Joan S Brugge
Journal:  JCI Insight       Date:  2016-07-07

7.  Testing the gene expression classification of the EMT spectrum.

Authors:  Dongya Jia; Jason T George; Satyendra C Tripathi; Deepali L Kundnani; Mingyang Lu; Samir M Hanash; José N Onuchic; Mohit Kumar Jolly; Herbert Levine
Journal:  Phys Biol       Date:  2019-01-18       Impact factor: 2.583

8.  MicroRNA (miR)-203 and miR-205 expression patterns identify subgroups of prognosis in cutaneous squamous cell carcinoma.

Authors:  J Cañueto; E Cardeñoso-Álvarez; J L García-Hernández; P Galindo-Villardón; P Vicente-Galindo; J L Vicente-Villardón; D Alonso-López; J De Las Rivas; J Valero; E Moyano-Sanz; E Fernández-López; J H Mao; A Castellanos-Martín; C Román-Curto; J Pérez-Losada
Journal:  Br J Dermatol       Date:  2017-05-08       Impact factor: 9.302

Review 9.  Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Authors:  Woonyoung Choi; Bogdan Czerniak; Andrea Ochoa; Xiaoping Su; Arlene Siefker-Radtke; Colin Dinney; David J McConkey
Journal:  Nat Rev Urol       Date:  2014-06-24       Impact factor: 14.432

10.  MAWBP and MAWD inhibit proliferation and invasion in gastric cancer.

Authors:  Dong-Mei Li; Jun Zhang; Wen-Mei Li; Jian-Tao Cui; Yuan-Ming Pan; Si-Qi Liu; Rui Xing; You-Yong Lu
Journal:  World J Gastroenterol       Date:  2013-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.